APO-T is a biopharmaceutical company focused on the development and commercialization of proprietary biotherapeutics for oncology.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/apo-t-bv” connections=”true” suffix=””]
APO-T has developed proprietary molecules that are capable of targeting any tumor cell that expresses a specific MAGE-A peptide in the context of the MHC-1 complex (MAGE-MHC-1 peptide complex).
In March 2013, LinXis granted APO-T an exclusive worldwide license for the development and commercialization of fully-human antibody-drug-conjugates using APO-Ts MAGE-HLA targeted antibodies and LinXis unique LX linker technology. In exchange, LinXis will receive milestone payments and royalties.
In April 2014, The Netherlands Enterprise Agency (RvO) grants APO-T an _Innovation CreditÓ of 1.5 Mn to support preclinical studies and a planned Phase I/II study for its AIM therapy, designed for the treatment of AML/MM.